<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA: Facial Rejuvenation - Nonsurgical Topic Collection</title>
    <link>http://jama.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 26 Nov 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:46:50 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@jama.jamanetwork.com</managingEditor>
    <webMaster>webmaster@jama.jamanetwork.com</webMaster>
    <item>
      <title>Botox Risks Under Review</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=181673</link>
      <pubDate>Wed, 26 Mar 2008 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;Patients treated with botulinum toxin type A (Botox and Botox Cosmetic) and botulinum toxin type B (Myobloc) for a variety of conditions have experienced adverse reactions, including respiratory failure and death, according to a February notice from the FDA.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">299</prism:volume>
      <prism:number xmlns:prism="prism">12</prism:number>
      <prism:startingPage xmlns:prism="prism">1417</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">1417</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.299.12.1417-d</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=181673</guid>
    </item>
  </channel>
</rss>